JP2006508965A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508965A5 JP2006508965A5 JP2004551895A JP2004551895A JP2006508965A5 JP 2006508965 A5 JP2006508965 A5 JP 2006508965A5 JP 2004551895 A JP2004551895 A JP 2004551895A JP 2004551895 A JP2004551895 A JP 2004551895A JP 2006508965 A5 JP2006508965 A5 JP 2006508965A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- heterocyclyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000001072 heteroaryl group Chemical group 0.000 claims 49
- 229910005965 SO 2 Inorganic materials 0.000 claims 43
- 125000003118 aryl group Chemical group 0.000 claims 42
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 40
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 22
- -1 aryl-C 1 -C 4 alkyl- Chemical group 0.000 claims 20
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 241000124008 Mammalia Species 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims 6
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 5
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 5
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 5
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 230000033115 angiogenesis Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- 102000001301 EGF receptor Human genes 0.000 claims 3
- 108060006698 EGF receptor Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 3
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 3
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000006203 morpholinoethyl group Chemical group [H]C([H])(*)C([H])([H])N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 230000008728 vascular permeability Effects 0.000 claims 3
- 102000044591 ErbB-4 Receptor Human genes 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims 2
- 108010090091 TIE-2 Receptor Proteins 0.000 claims 2
- 102000012753 TIE-2 Receptor Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 102000009929 raf Kinases Human genes 0.000 claims 2
- 108010077182 raf Kinases Proteins 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims 1
- 108091008606 PDGF receptors Proteins 0.000 claims 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42422302P | 2002-11-06 | 2002-11-06 | |
| PCT/US2003/035588 WO2004043379A2 (en) | 2002-11-06 | 2003-11-06 | Chemical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508965A JP2006508965A (ja) | 2006-03-16 |
| JP2006508965A5 true JP2006508965A5 (enExample) | 2006-12-21 |
Family
ID=32312770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004551895A Withdrawn JP2006508965A (ja) | 2002-11-06 | 2003-11-06 | 化学物質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060241149A1 (enExample) |
| EP (1) | EP1581514A2 (enExample) |
| JP (1) | JP2006508965A (enExample) |
| AR (1) | AR041992A1 (enExample) |
| AU (1) | AU2003290661A1 (enExample) |
| TW (1) | TW200418466A (enExample) |
| WO (1) | WO2004043379A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| WO2005070891A2 (en) * | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
| PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| ES2450566T3 (es) | 2004-11-30 | 2014-03-25 | Amgen Inc. | Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| ES2761180T3 (es) | 2005-12-23 | 2020-05-19 | Ariad Pharma Inc | Compuestos bicíclicos de heteroarilo |
| GB0604937D0 (en) * | 2006-03-10 | 2006-04-19 | Novartis Ag | Organic compounds |
| GB0605120D0 (en) * | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| JP5273037B2 (ja) | 2006-05-08 | 2013-08-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | アセチレン性ヘテロアリール化合物 |
| EP2017263A4 (en) * | 2006-05-09 | 2011-11-30 | Daiichi Sankyo Co Ltd | Heteroarylamide derivative of a lower carboxylic acid |
| BRPI0810028A2 (pt) * | 2007-04-17 | 2014-10-21 | Novartis Ag | Éteres de amidas de ácido naftaleno carboxílico no tratamento de câncer |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| CA3167093A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| CN104496995A (zh) * | 2014-01-06 | 2015-04-08 | 广东东阳光药业有限公司 | 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法 |
| CN110483482A (zh) * | 2018-05-15 | 2019-11-22 | 北京诺诚健华医药科技有限公司 | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
| US20240067657A1 (en) * | 2020-12-29 | 2024-02-29 | Merck Sharp & Dohme Llc | Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses |
| JPWO2022250108A1 (enExample) * | 2021-05-26 | 2022-12-01 | ||
| CN116265452A (zh) * | 2021-12-17 | 2023-06-20 | 中国科学院上海药物研究所 | 含氮杂环化合物、其制备方法及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230302B1 (hu) * | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
-
2003
- 2003-11-04 TW TW092130770A patent/TW200418466A/zh unknown
- 2003-11-04 AR ARP030104037A patent/AR041992A1/es unknown
- 2003-11-06 WO PCT/US2003/035588 patent/WO2004043379A2/en not_active Ceased
- 2003-11-06 AU AU2003290661A patent/AU2003290661A1/en not_active Abandoned
- 2003-11-06 US US10/533,832 patent/US20060241149A1/en not_active Abandoned
- 2003-11-06 JP JP2004551895A patent/JP2006508965A/ja not_active Withdrawn
- 2003-11-06 EP EP03783243A patent/EP1581514A2/en not_active Withdrawn